Prostate Cancer Risk Reduction sNDAs Go Before ODAC, Pitting Statistical Versus Clinical Significance
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Avodart and Merck's Proscar reduce the risk of low-grade prostate cancers in trials, but FDA's Oncologic Drugs Advisory Committee will hear the agency argue on Dec. 1 that the actual benefit of this is questionable.
You may also be interested in...
GSK Loses Bid For Avodart Prostate Cancer Prevention Indication
FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.
GSK Loses Bid For Avodart Prostate Cancer Prevention Indication
FDA's "complete response" letter would appear to dampen the company's most lucrative opportunity for expanding the benign prostatic hyperplasia drug's indication before entry of generic competition.
Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs
The problems that GlaxoSmithKline and Merck had in trying to convince FDA's Oncologic Drugs Advisory Committee to add labeling on prostate cancer risk reduction to Avodart (dutasteride) and Proscar (finasteride) may have been avoided had the firms selected a stronger mortality endpoint for their trials.